Epigenetics and Non-Coding RNAs in Multiple Myeloma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 15 February 2026 | Viewed by 49
Special Issue Editor
2. Clinical Hematology, FMUP–Faculty of Medicine, University of Porto, Porto, Portugal
3. 1i3S–Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal
Interests: EVs; microRNAs; drug resistance; immunotherapy; multiple myeloma
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to an upcoming Special Issue entitled “Epigenetics and Non-Coding RNAs in Multiple Myeloma”, to be published in Cancers. This Issue aims to highlight emerging research at the interface of epigenetic regulation and non-coding RNA biology, with a focus on their roles in the pathogenesis, progression, drug resistance, and therapeutic targeting of multiple myeloma (MM).
Recent advances underscore the importance of DNA methylation, histone modifications, and non-coding RNAs—particularly microRNAs, long non-coding RNAs, and circular RNAs—in shaping MM biology and patient outcomes. This Special Issue seeks to gather original research articles, reviews, and perspectives that provide mechanistic insights or translational relevance, ultimately aiming to drive forward precision medicine strategies in MM.
We look forward to your valuable contribution to this timely and impactful collection.
Dr. Rui Bergantim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- epigenetics
- non-coding RNAs
- microRNAs (miRNAs)
- long non-coding RNAs (lncRNAs)
- circular RNAs (circRNAs)
- DNA methylation
- histone modifications
- drug resistance
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
